Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 8;9(7):e002267. doi: 10.1136/jitc-2020-002267

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Screening of cytokines and growth factors secreted from exPBNK regulated by GBM cells with/without Dinutuximab +N-803. Purified exPBNK cells were cultured in medium with M059K (GBM) tumor cells with/without IgG, dinutuximab, N-803, or dinutuximab +N-803 for 3 days. GBM tumor cells cultured in medium were used as controls. The supernants were collected after 3 days culture and used for Bio-Plex pro human cytokines screening panel 48 cytokines assay. (A) The combination of exPBNK +N-803+ dinutuximab reduced the secretion of TRAIL, PDGF-BB, and SCGF-β from GBM tumor cells (p<0.001). (B) GBM significantly inhibited the secretion of RATNES and SDF-1α from exPBNK cells (p<0.001). (C) GBM significantly enhanced MIG secreted from exPBNK cells (p<0.001). (D) The combination of GBM, N-803 and dinutuximab significantly enhanced the secretion of MIP-1beta from exPBNK cells (p<0.001). (E) The combination of exPBNK+N-803+ dinutuximab significantly reduced the secretion of PDGF-AA from OS or GBM tumor cells (p<0.001). NK=exPBNK, Dinu=dinutuximab, OS=U2OS cell line, GBM=M059K cell line. Data were presented as mean±SEM from three independent experiments. GBM, glioblastoma multiforme; exPBNK, expanded peripheral blood natural killer cell; NK, natural killer; OS, osteosarcoma; TRAIL, tumor factor-related apoptosis-inducing ligand; PDGF, platelet-derived growth factor; RANTES, regulated uponon activation, normal T cell expressed and presumably secreted; SDF, stromal cell-derived factor; SCGF, stem cell growth factor; MIG, Monokine induced by gamma interferon; MIP, macrophage inflammatory proteins.